A latest study conducted by the Journal of Clinical Oncology states that one in three relapsed or treatment-resistant B-cell acute lymphoblastic leukemia (R/R B-ALL) patients remained in long-term remission post-CAR T-cell therapy obecabtagene autoleucel (obe-cel) – a novel advancement in cancer immunotherapy. In the latest FELIX trial updates, medical researchers observed that 40% patients were […]